8-Aminoquinoline Therapy for Latent Malaria

@article{Baird20198AminoquinolineTF,
  title={8-Aminoquinoline Therapy for Latent Malaria},
  author={J. Kevin Baird},
  journal={Clinical Microbiology Reviews},
  year={2019},
  volume={32}
}
  • J. Baird
  • Published 2019
  • Medicine
  • Clinical Microbiology Reviews
The technical genesis and practice of 8-aminoquinoline therapy of latent malaria offer singular scientific, clinical, and public health insights. The 8-aminoquinolines brought revolutionary scientific discoveries, dogmatic practices, benign neglect, and, finally, enduring promise against endemic malaria. SUMMARY The technical genesis and practice of 8-aminoquinoline therapy of latent malaria offer singular scientific, clinical, and public health insights. The 8-aminoquinolines brought… Expand
Chloroquine Potentiates Primaquine Activity against Active and Latent Hepatic Plasmodia Ex Vivo: Potentials and Pitfalls
TLDR
It is concluded that chloroquine specifically potentiated 8-aminoquinoline activities against active and dormant hepatic-stage plasmodia in normal primary hepatocytes but not in a hepatocarcinoma cell line. Expand
Enantioselective Interactions of Anti-Infective 8-Aminoquinoline Therapeutics with Human Monoamine Oxidases A and B †
TLDR
Differential interactions of PQ and NPC1161 enantiomers with human MAOs may contribute to the enantioselective pharmacodynamics and toxicity of anti-infective 8-AQs therapeutics. Expand
Basic Research of Plasmodium vivax Biology Enabling Its Management as a Clinical and Public Health Problem
  • J. Baird
  • Medicine
  • Frontiers in Cellular and Infection Microbiology
  • 2021
TLDR
This Review expresses how clarity of vision of biology and pathogenesis may rationally and radically transform the multiple means by which the authors may combat this insidiously harmful infection. Expand
Anti‐malarial drug effects on parasite dynamics in vivax malaria
TLDR
The dose–response relationship for radical curative efficacy of primaquine and tafenoquine is steep over the total dose range from 1.5 to 5 mg base/kg which may explain the poor efficacy of tafanoquine at the currently recommended dose. Expand
Monitoring Plasmodium vivax resistance to antimalarials: Persisting challenges and future directions
TLDR
The challenges for assessing in vivo P. vivax responses to commonly used antimalarials, especially chloroquine and primaquine, in the presence of confounding factors such as variable drug absorption, metabolism and interaction are reviewed. Expand
The role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases.
TLDR
Evidence has shown that these structures are leader molecules that can be modified or combined with other therapeutic agents, and the use of these antimalarial drugs on diseases. Expand
Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function
TLDR
It is highlighted the importance of considering the analysis of CYP2D6 gene polymorphisms in cases of P. vivax relapses after a correct treatment and, especially, it should be considered in any study of dosage and duration of primaquine treatment. Expand
CYP2D6 Genetic Variation and Its Implication for Vivax Malaria Treatment in Madagascar
TLDR
The present study sought to characterize CYP2D6 genetic variation in Madagascar, where populations originated from admixture between Asian and African populations, vivax malaria is endemic, and PQ can be deployed soon to achieve national malaria elimination, and provides fresh insights about genomic characteristics that could affect the metabolism of PQ into its active state. Expand
A New Thienopyrimidinone Chemotype Shows Multistage Activity against Plasmodium falciparum, Including Artemisinin-Resistant Parasites
This work reports a new chemical structure that (i) displays activity against the human malaria parasite Plasmodium falciparum at 3 stages of the parasitic cycle (blood stage, hepatic stage, andExpand
Elimination of Plasmodium vivax Malaria: Problems and Solutions
TLDR
The continued challenges to effectively control P. vivax are reviewed and integrated technologies and targeted strategies for the elimination of the parasite are explored. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 454 REFERENCES
New tissue schizontocidal antimalarial drugs.
TLDR
The most active member of this series, 4-methyl-5-phenoxy-6-methoxy-8-aminoquinolines, was 5 times more active than primaquine in curing persistent exoerythrocytic infections of P. cynomolgi in rhesus monkeys. Expand
Use of quinocide in treatment and prophylaxis of vivax malaria.
TLDR
It is suggested that the mass administration of quinocide would in certain cases be a useful adjunct to insecticidal measures in the clearance of malaria foci. Expand
3. TOXICITY OF PRIMAQUINE IN CAUCASIANS
TLDR
Combined action of the two drugs has been exploited during the transpacific voyage to achieve radical cure of vivax infections before symptoms have developed. Expand
4. TOXICITY OF PRIMAQUINE IN NEGROES
TLDR
Hemolytic reactions during antimalarial therapy have proved to be a limiting factor in the use of 8-aminoquinolines for the cure of vivax malaria and are higher in the dark-skinned races. Expand
Origins and implications of neglect of G6PD deficiency and primaquine toxicity in Plasmodium vivax malaria
  • K. Baird
  • Medicine
  • Pathogens and global health
  • 2015
TLDR
This review offers critical historic reflection on the neglect of this serious problem in the chemotherapy of P. vivax, where providers must choose between risking harm by the parasite or its treatment. Expand
Conflicts of interest: the genesis of synthetic antimalarial agents in peace and war.
  • D. Greenwood
  • Medicine
  • The Journal of antimicrobial chemotherapy
  • 1995
TLDR
A massive cooperative screening programme in the USA during World War II eventually bore fruit in the realization of the therapeutic potential of chloroquine, and in the later development of amodiaquine and primaquine. Expand
STUDIES ON THE CHEMOTHERAPY OF THE HUMAN MALARIAS. VII. THE ANTIMALARIAL ACTIVITY OF PAMAQUINE.
TLDR
The toxicity of the drug and an incomplete understanding of the biology of vivax malaria led the commission on malaria to state that its prophylactic action was not practical and to discount the work of Sinton on its curative action. Expand
Therapeutic Responses to Different Antimalarial Drugs in Vivax Malaria
TLDR
Therapeutic responses to PS were poor; parasitemias did not clear in 5 of the 12 PS-treated patients, whereas all the other patients made an initial recovery, suggesting suppression of the first relapse by these slowly eliminated drugs. Expand
Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms
TLDR
Taking together, the estimated frequencies of these primaquine ineligibles due to G6PD toxicity or impaired CYP2D6 activity composed over 35% of the populations at risk of vivax malaria. Expand
Primaquine toxicity forestalls effective therapeutic management of the endemic malarias.
  • J. Baird
  • Medicine, Biology
  • International journal for parasitology
  • 2012
TLDR
Despite being licensed over 50 years ago, no alternative drugs have been developed, and safer dosing regimens of primaquine have not been explored, forestalled the emergence of therapies practical for use in endemic zones, especially in the context of eliminating transmission. Expand
...
1
2
3
4
5
...